Publish in this journal
Journal Information
Vol. 70. Issue 4.
Pages 309 (April 2017)
Corrections
DOI: 10.1016/j.rec.2016.11.034
Full text access
Correction to the Article by Dalama et al. “New Oral Hypoglycemic Agents and Cardiovascular Risk. Crossing the Metabolic Border”. Rev Esp Cardiol. 2016;69:1088-1097
Corrección en el artículo de Dalama et al. «Nuevos hipoglucemiantes orales y riesgo cardiovascular. Cruzando la frontera metabólica». Rev Esp Cardiol. 2016;69:1088-1097
Visits
...
Related content
Rev Esp Cardiol. 2016;69:1088-9710.1016/j.rec.2016.07.008
Belén Dalama, Jordi Mesa
This item has received
...
Visits
(Daily data update)
Article information
Full Text
Download PDF
Statistics
Tables (1)
Table 2. Indications for Sodium-glucose Cotransporter 2 Inhibitor Initiation and Dose Adjustment Based on Glomerular Filtration Rate and Age
Full Text

In the article by Dalama et al. “New oral hypoglycemic agents and cardiovascular risk. Crossing the metabolic border” published in Rev Esp Cardiol. 2016;69:1088-97, the following information has been added in the Table 2:

Table 2.

Indications for Sodium-glucose Cotransporter 2 Inhibitor Initiation and Dose Adjustment Based on Glomerular Filtration Rate and Age

  eGFR ≥ 60 mL/min/1.73 m2  eGFR ≥ 45-60 mL/min/1.73 m2  eGFR ≥ 30-45 mL/min/1.73 m2  eGFR<30 mL/min/1.73 m2  Age 
Dapagliflozin  • Start with 10 mg/daya  • Do not start
• Discontinue if receiving treatment and GFR<60b 
• Do not start
• Discontinue if receiving treatment 
• Do not start
• Discontinue if receiving treatment 
<75 y 
Empagliflozin  • Start with 10 mg/day
• Increase to 25 mg/day if there is good tolerance and need for better glycemic control 
• Start with 10 mg/day*
• Increase to 25 mg/day if there is good tolerance and need for better glycemic control 
• Do not start
• Discontinue if receiving treatment and GFR<45b 
• Do not start
• Discontinue all drug doses 
<85 yc 
Canagliflozind  • Start with 100 mg/day
• Increase to 300 mg/day if there is good tolerance and need for better glycemic control 
• Start with 100 mg/day and do not increase**
• Reduce to 100 mg/day if patient is being treated with 300 mg 
• Do not start
• Discontinue if receiving treatment and GFR<45b 
• Do not start
• Discontinue all drug doses 
>18 ye 

eGFR, estimated glomerular filtration rate; EMA, European Medicines Agency; FDA, Food and Drug Administration; GFR, glomerular filtration rate.

a

Patients with liver failure should be started on 5mg/day.

b

Persistent.

c

Warning of possible hypovolemia in patients older than 75 years.

d

Although its pharmacokinetics are not affected by food, it should be taken before the first food intake of the day due to its potential ability to delay intestinal absorption of glucose.

e

Precaution should be exercised before the dose is increased in patients older than 75 years.

*

Approved by the FDA. The EMA recommends not starting this drug if GFR<60, but if treatment has already started, the dose should be reduced to 10mg/day.

**

Approved by the FDA. The EMA recommends not starting this drug if GFR<60.

*Approved by the FDA. The EMA recommends not starting this drug if GFR < 60, but if treatment has already started, the dose should be reduced to 10mg/day.

**Approved by the FDA. The EMA recommends not starting this drug if GFR < 60.

The correct table is:

This correction was introduced in the electronic version of the article on 9/12/2016.

Idiomas
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?